Swallowing in the first year after chemoradiotherapy for head and neck cancer: clinician- and patient-reported outcomes

Head Neck. 2014 Mar;36(3):352-8. doi: 10.1002/hed.23306. Epub 2013 Jun 18.

Abstract

Background: This prospective study evaluated swallowing outcomes prechemoradiotherapy (pre-CRT) up to 1 year post-CRT, in a substantial cohort of patients with head and neck cancer and explored factors predicting outcome.

Methods: One hundred twelve patients were assessed pretreatment and at 3, 6, and 12 months posttreatment using a questionnaire, endoscopic assessment, water swallow test, and diet score.

Results: Seventy-one patients were retained, the majority had oropharyngeal (53%) or hypopharyngeal cancer (20%). A marked deterioration occurred between pretreatment and 3 months posttreatment (p ≤ .01). Significant improvement between 3 and 12 months was found on 2 swallowing measures, but not self reported. Three of the 4 pretreatment assessments predicted outcomes at 1 year.

Conclusion: CRT results in a marked deterioration on different paradigms of swallowing measurements. Improvement occurs on some clinical measures, but limited change is observed in patients' perceptions. Pretreatment measures are important indicators of long-term dysphagia. Swallowing recovery is complex, taking different courses between clinical tests and perspectives.

Keywords: chemoradiotherapy; dysphagia; head and neck cancer; swallowing assessment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use
  • Chemoradiotherapy*
  • Cisplatin / therapeutic use
  • Deglutition Disorders / etiology
  • Deglutition*
  • Female
  • Head and Neck Neoplasms / physiopathology
  • Head and Neck Neoplasms / therapy*
  • Humans
  • Hypopharyngeal Neoplasms / therapy
  • Laryngeal Neoplasms / therapy
  • Male
  • Middle Aged
  • Mitomycin / therapeutic use
  • Nasopharyngeal Neoplasms / therapy
  • Oropharyngeal Neoplasms / therapy
  • Prospective Studies
  • Radiotherapy Dosage
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Mitomycin
  • Cisplatin